Introduction: Tumor biopsies for detecting EGFR mutations in advanced NSCLC are invasive, costly, and not always feasible for patients with late-stage disease. The clinical utility of the cobas EGFR Mutation Test v2 (Roche Molecular Systems, Inc., Pleasanton, CA) with plasma samples from patients with NSCLC at disease progression after previous EGFR tyrosine kinase inhibitor therapy was investigated to determine eligibility for osimertinib treatment.
Introduction
The EGFR tyrosine kinase inhibitors (TKIs), including erlotinib, afatinib and gefitinib, are recommended first-line treatments for patients with EGFR mutationpositive, advanced NSCLC. [1] [2] [3] [4] [5] [6] [7] [8] [9] Resistance develops in most patients with EGFR mutation-positive NSCLC treated with a first-line EGFR TKI, [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] and approximately 60% of these patients have tumors that harbor an EGFR T790M resistance mutation. 11, 12 Analysis of tumor tissue biopsy material is considered the conventional standard method for mutation detection. The biopsy tissue sample is typically formalin-fixed and paraffin-embedded before DNA is extracted and analyzed to detect EGFR mutations. Obtaining sufficient tumor tissue for analysis from patients with advanced NSCLC who progressed during a previous therapy is invasive and time-and resourceintensive, and such biopsies are associated with a higher risk for complications to the patient. 13 In cases in which it is not possible to obtain a tumor biopsy sample, patients who would otherwise be eligible may not be provided with access to potentially beneficial targeted therapies. Therefore, there is a clear unmet clinical need for an alternative procedure to detect the EGFR T790M mutation in the EGFR TKI resistance setting.
Circulating tumor DNA (ctDNA) has been identified as a specific and sensitive biomarker that can be used for the detection of EGFR mutations. [14] [15] [16] [17] ctDNA comprises small fragments of DNA that are shed from tumor cells during processes such as apoptosis and necrosis. ctDNA can be extracted from plasma and serum and can be tested for tumor-specific molecular markers. 18, 19 The cobas EGFR Mutation Test v2 (Roche Molecular Systems, Inc., Pleasanton, CA) has been developed for detection of EGFR mutations in both tumor tissue and plasma samples.
Osimertinib is a potent oral, irreversible EGFR TKI that is selective for both EGFR TKI-sensitizing mutations and T790M resistance mutations over the wild-type EGFR. 20 Osimertinib is recommended for the treatment of patients with EGFR T790M-positive NSCLC after progression during a first-line EGFR TKI treatment. 1, 2 The AURA clinical trial program includes two key phase II studies to assess the efficacy and safety of osimertinib in patients with T790M mutation-positive advanced NSCLC who have progressed after EGFR TKI treatment. The AURA extension (NCT01802632) and AURA2 (NCT02094261) studies (phase II), which were used for conditional approval of osimertinib, investigated the efficacy, tolerability, and safety of orally administered osimertinib in patients with T790M mutation-positive advanced NSCLC. 21, 22 Central detection of the T790M mutation in a tumor tissue sample by using the cobas EGFR Mutation Test v2 (European Conformity research use-only, investigational use-only version) was required for enrollment in these clinical studies. The purpose of this analysis is to assess the clinical utility of the cobas plasma test for detection of the T790M mutation in ctDNA obtained from patient plasma samples collected during screening for the AURA extension and AURA2 studies.
Methods

Study Design and Participants
Full details of the AURA extension and AURA2 studies have been previously published. 21, 22 In brief, the AURA extension and AURA2 studies were phase II, single-arm, open-label, multicenter studies of osimertinib, 80 mg orally once daily. Patients were at least 18 years old (21 years in Japan) with advanced NSCLC, and they had disease progression after treatment with an EGFR TKI agent or had received prior therapy with an EGFR TKI and at least one other treatment regimen. Radiological documentation of disease progression during the last treatment administered before enrollment in the studies was required. At baseline all patients were required, on confirmation of disease progression during or after their most recent treatment regimen, to provide a tumor biopsy sample for central T790M analysis. During the screening period, patients were also required to provide plasma samples for retrospective analysis. These studies were designed to assess the efficacy, safety, and tolerability of osimertinib.
The studies were approved by the institutional review board or independent ethics committee associated with each study center. All patients provided written informed consent before any study-specific procedures, sampling, and analyses were performed. Patients who stopped participating in the study for any reason other than disease progression continued with tumor assessments until disease progression. The primary end point of the studies was objective response rate (ORR), defined by blinded independent central review (BICR) using the Response Criteria in Solid Tumors, version 1.1. The efficacy of osimertinib was assessed according to cobas tumor tissue (primary study objective) and plasma test (exploratory objective) results for T790M mutation status.
Tumor Tissue and Plasma Sampling
A mandatory tissue biopsy sample was taken from all patients after confirmation of disease progression during the last treatment regimen. Tumor tissue biopsy and plasma samples were collected from patients being screened for the AURA extension and AURA2 clinical studies. All plasma samples were collected during the initial 28-day baseline period before dosing with osimertinib.
DNA Extraction, Amplification, and Detection
The tumor tissue samples were formalin-fixed and paraffin-embedded, and genomic DNA was extracted from them for mutation testing. The concentration of genomic DNA from the extracted tissue sample was determined with a spectrophotometer and adjusted to 2 ng/mL. The cobas cell-free DNA Sample Preparation Kit (Roche Molecular Systems) was used to extract the ctDNA from the plasma samples. The cobas EGFR Mutation Test (investigational use-only version [Roche Molecular Systems]) was used to detect EGFR mutations in the extracted tissue DNA samples (from here on referred to as the cobas tissue test). The cobas EGFR Mutation Test v2 (European Conformity investigational use-only version [Roche Molecular Systems]) was used to detect EGFR mutations in the extracted plasma ctDNA (from here on referred to as the cobas plasma test). Amplification and detection were attained by using target-specific primer and probe sequences. These tests were performed at three central testing laboratories: Carolinas Pathology Group (Charlotte, NC), Histogenex (Antwerp, Belgium), and Quintiles (Singapore). Assays were performed according to the manufacturer protocols. Detectable EGFR mutations were reported as positive in the analysis output. EGFR mutations below the detectable limit were reported as negative. Any invalid cobas test results were reported as status unknown; these samples were excluded from all corresponding analyses unless stated otherwise. MiSeq sequencing (Illumina, San Diego, CA) was used as the comparator method for the cobas test. MiSeq utilizes deep sequencing of EGFR exons 18, 19, 20, and 21. Deep sequencing, or next-generation sequencing (NGS), is a suitable comparator for the polymerase chain reaction (PCR)-based EGFR mutation detection test because it has very low analytical sensitivity (around 1%-2%). 23 Illumina's MiSeq sequencing can provide a high depth of coverage to identify the prevalence of low-frequency mutations. The MiSeq NGS data were generated by using a two-tube amplicon assay. Testing was performed at Roche Molecular Systems laboratories or SeqWright (Houston, TX).
Assessments
Clinical efficacy was evaluated as the primary end point, with ORR determined by BICR in the evaluable-for-response populations from both the AURA extension and AURA2 trials. The evaluable-for-response patient group included those patients with at least one lesion at baseline that was measureable by BICR.
Statistical Methods
The clinical efficacy data is based on a data cutoff date of November 1, 2015, for both the AURA extension and AURA2 trials. The agreement between the cobas tumor tissue test and cobas plasma test for each EGFR mutation subtype was assessed for sensitivity by calculating the positive percent agreement (PPA), specificity by calculating the negative percent agreement (NPA), and concordance by calculating the overall percent agreement (OPA) with 95% confidence intervals (CIs), with the cobas tumor tissue test used as the reference method. The calculations for these values are outlined in Supplementary Table 1 . CIs were calculated by using the Clopper-Pearson exact method for binomial proportions. The ORR data analysis was performed with the evaluable-for-response patients, defined as all patients who received at least one dose of study treatment and had measureable disease at baseline according to the BICR.
Results
Patient EGFR Mutation Status
There were 401 and 472 patients screened for the AURA extension and AURA2 studies, respectively. In the AURA extension study, 210 screened patients provided matched tumor tissue and plasma samples, whereas 341 screened patients provided matched tumor tissue and plasma samples in the AURA2 study ( Fig. 1) . Thus, a total of 551 out of 710 (78%) patients with a cobas tissue test provided matched tumor tissue and plasma samples. These comprised 416 T790M-positive, 127 T790M-negative, and eight invalid results according to the cobas tissue test. Fewer plasma samples were provided from patients with a negative T790M tissue test result than from those with a positive T790M tissue test result. This was a consequence of sample collection during the AURA extension study, as plasma samples tended to be collected from patients only after tissue test results were known. This resulted in fewer plasma samples from patients with a negative tissue test result who were ineligible for the AURA extension study. During Table 2 ).
Percent Agreement Between the cobas Plasma Test and cobas Tissue Test
The cobas tissue test was used as a reference method to assess the sensitivity, specificity, and concordance of the cobas plasma test for detection of T790M, L858R, and exon 19 deletion mutations (Table 2 ). For the screened patient population from the AURA extension study, the PPA for the T790M mutation was 64% (95% CI: 57-71). The NPA value is not reported because the total number of matched patient samples was less than 20. In the screened patient population from the AURA2 study, the PPA for the T790M mutation was 59% (95% CI: 52-65) and the NPA was 80% (95% CI: 72-87). When the AURA extension and AURA2 data were pooled, the PPA and NPA were 61% (95% CI: 57-66) and 79% (95% CI: 70-85), respectively, and the OPA was 65% (95% CI: 61-69) for the T790M mutation. The PPA for T790M detection increased slightly and the NPA decreased slightly when patients with neither T790M nor sensitizing EGFR mutations (G719X, exon 19 deletion, S7681, exon 20 insertion, and L858R) detected in plasma by cobas were excluded from the agreement calculations (n ¼ 101 in the pooled data set): the PPA was 72% (95% CI: 67-77) and the NPA was 69% (95% CI: 59-79) (Supplementary Table 3 Table 4 ). In patients whose line of therapy was unknown, the NPA was 79% (95% CI
From the pooled data set, comparing the cobas plasma test results with the cobas tissue test results produced PPA, NPA, and OPA values for the detection of L858R mutation of 76% (95% CI: 69-82), 98% (95% CI: 96-99), and 91% (95% CI: 88-93), respectively. For detection of the exon 19 deletions, the PPA, NPA and OPA values were 85% (95% CI: 81-89), 98% (95% CI: 95-100), and 90% (95% CI: 87-92), respectively ( Table 2) .
cobas and MiSeq NGS Concordance for Tumor Tissue and Plasma Samples
The cobas plasma test results were compared with a reference NGS method with plasma samples for detection of T790M in ctDNA (MiSeq). For detection of the T790M mutation, the PPA, NPA, and OPA values were 93% (95% CI: 89-96), 92% (95% CI: 88-95), and 92% (95% CI: 90-94), respectively (Table 3) . This is comparable with the PPA, NPA, and OPA values with the cobas tissue test when compared with a reference NGS method with tumor tissue samples (Table 3) . 24 Five patients screened for AURA extension and 22 patients for AURA2 were genotyped as T790M positive with the cobas plasma test and T790M negative with the cobas tissue test. These discordances were assessed further by using NGS results (Table 4) . Twenty-three of the 27 discordant plasma samples were confirmed as T790M positive by the NGS plasma test, one plasma 
Objective Response Rate Based on the cobas Tissue and Plasma Tests for T790M Mutation Status
In the AURA extension study patients selected by using the cobas tissue test and meeting the evaluable-for-response criteria (n ¼ 198), the ORR, as previously reported, was 62% (95% CI: 54-68) ( Table 5) . 21 In the subset of those patients who also had a plasma T790M-positive result (n ¼ 126), the ORR was very similar: 59% (95% CI: 50-67). Likewise, the AURA2 study patients selected by using the cobas tissue test and meeting the evaluable-for-response criteria (n ¼ 199) had an ORR, as previously reported, of 70% (95% CI: 64-77), 22 and in the subset of those patients with a plasma T790M-positive result (n ¼ 109), the ORR was 70% (95% CI: 60-78). When the AURA extension and AURA2 data were pooled, the ORR in the evaluablefor-response analysis set with a tissue T790M-positive test was 66% (95% CI: 61-71); it was 64% (95% CI: 57-70) in the subset of patients who were also plasma T790M-positive.
Discussion
The cobas EGFR Mutation Test v2, which is suitable for use with both tumor tissue and plasma samples, has been developed as a diagnostic tool to help identify patients with T790M mutation-positive tumors for treatment with osimertinib. This analysis investigated the sensitivity, specificity, and concordance of the cobas plasma test for the detection of EGFR mutations, with a focus on the T790M mutation when compared with the cobas tissue test. The MiSeq Illumina NGS method was used as a reference test.
The PPA value for detection of T790M mutation in the pooled data set when comparing cobas plasma with cobas tissue as a reference was 61%, meaning that this subgroup of patients could have had their T790M mutation status determined without an invasive biopsy procedure. This is consistent with previous reports of EGFR mutation status investigated with tumor tissue and plasma samples.
14 When the cobas plasma test results and the cobas tissue test results are compared, the PPA for the detection of T790M is somewhat lower than the PPA for L858R and exon 19 deletions (76% and 85%, respectively [pooled data set]). This is also consistent with other reports of plasma testing in the EGFR TKI NGS, next-generation sequencing; CI, confidence interval; PPA, positive percent agreement (sensitivity); NPA, negative percent agreement (specificity); OPA, overall percent agreement (concordance).
resistance setting [25] [26] [27] and likely due to tumor heterogeneity and a lower abundance of the resistance mutation than the driver mutation in the advanceddisease setting. The likelihood of detection of T790M in the plasma of patients with a T790M-positive tissue test result is greater in the subcategory of patients with extrathoracic disease (TNM seventh edition category M1B) than in those with intrathoracic disease (M0-M1A): 72% and 51%, respectively (p ¼ 0.0001, see Table 1 ). One possibility is that patients with NSCLC who have extrathoracic disease may have a higher disease burden and are therefore more likely to shed tumorderived DNA into their bloodstream. This is supported by the positive correlation between the baseline target lesion size and positive detection of T790M by plasma test. Furthermore, in patients who received osimertinib as a second-line therapy, PPA was lower (52%) than in those who received osimertinib as third-or later-line therapy (65%). This suggests that it is more challenging to detect T790M in plasma ctDNA of patients who have just progressed after a previous first-line EGFR TKI. We hypothesize that patients who received more previous lines of therapy may have a greater disease burden and a greater allelic fraction of T790M or that prior chemotherapy in some way promotes shedding of ctDNA from tumor cells. Therefore, further investigation into the reasons for higher detection of T790M in this subset of patients is warranted.
The plasma test did not detect the T790M mutation in plasma ctDNA of approximately 40% of patients with a T790M-positive tissue test result. To mitigate the risk for a false-negative plasma test result, it is advised that, where possible, any plasma T790M-negative test result be explored further with a contemporaneous biopsy and tissue test. This is also suggested in a recent study by Oxnard et al. 27 It has been suggested that detection of the original sensitizing mutation in plasma could act as an internal control for plasma testing; accordingly, a plasma sample with no detectable sensitizing mutation can be considered uninformative. Analysis of T790M PPA between the cobas plasma and tissue tests, excluding patients who had no detectable T790M or sensitizing mutation, resulted in a marginal increase in PPA (from 61% to 72%). We believe that caution should be applied when interpreting plasma results and recommend following up a plasma T790M-negative test result with a contemporaneous biopsy and tissue test whenever feasible.
The NPA for detection of T790M mutation in the pooled data set when the cobas plasma test result was compared with the cobas tissue test result as a reference was 79%, which is consistent with that reported by Oxnard et al. when using an alternative plasma testing method. 27 When the cobas plasma test result was compared with the cobas tissue test result, the NPA was notably lower for the T790M mutation than for L858R and exon 19 deletions. However, when the cobas plasma test results were also compared with the MiSeq NGS plasma results for detection of the T790M mutation, the PPA, NPA, and OPA values were all higher than 90%, demonstrating strong agreement between the two tests and confirming that the cobas plasma test reliably allows sensitive and specific detection of EGFR mutations in plasma. Furthermore, a low incidence of false-positive results from the cobas plasma test for T790M was demonstrated. In the 27 patients with T790M mutation-negative status by the cobas tissue test and T790M mutation-positive status by the cobas plasma test, 23 (85%) were T790M mutation-positive by the NGS reference method using plasma samples. These data suggest that the lower NPA value observed when comparing tumor tissue and plasma T790M results may be driven by tumor heterogeneity and not by poor specificity of the cobas plasma test.
The T790M mutation is an acquired drug resistanceassociated mutation and therefore reflects clonal evolution and increased tumor heterogeneity in the resistance setting. This is expected to contribute to the lower NPA between the plasma and tissue test results because obtaining tumor tissue by biopsy restricts sampling of tumor cells to a single site of disease. Thus, it is unsurprising that some discordance between tissue and plasma tests for the T790M mutation will be observed in the later-line setting. 28, 29 A limitation of this analysis is that patients were selected for the AURA extension and AURA2 clinical trials on the basis of tumor tissue T790M mutation status. Therefore, although these studies demonstrated similar ORRs in patients who were T790M mutationpositive according to the cobas tissue and plasma tests, preselection of patients by using the tissue test limits our assessment of efficacy in patients who would be selected by using a plasma test alone.
In addition to enabling a clinically significant proportion of patients to avoid a biopsy, a well-validated plasma test could benefit patients who are unable to provide a tumor tissue sample on account of the risks associated with the procedure. The overall performance status of a patient and the anatomical location of the site suitable for a biopsy are the most common limiting factors in performing these biopsies. 30, 31 Recent studies estimate that as many as 40% of relapsed patients with NSCLC may be unable to provide a contemporaneous tumor tissue sample suitable for molecular analysis. 30, 32 Performing the cobas plasma test is faster and cheaper than obtaining and processing tumor tissue samples, and this benefits both the patient and the health care provider. 31 This is in line with the increasing trend toward the development of liquidbased companion diagnostics. 33 For example, the cobas EGFR Mutation Test v2 is paired with erlotinib and osimertinib for NSCLC. 24 A limitation of ctDNA plasma testing is the higher probability of a falsenegative result. Therefore, after a plasma T790M negative cobas test result, it is advisable to obtain new biopsy material if possible to do so and perform a tissue test to determine the T790M status.
Other PCR-based assays that can be used to detect EGFR sensitizing mutations in plasma samples with varying specificity and sensitivity include the amplification refractory mutation system assay (therascreen EGFR RGQ PCR Kit [Qiagen, Hilden, Germany]); droplet digital PCR (ddPCR); and the beads, emulsions, amplification, and magnetics (BEAMing) ddPCR technique (Sysmex Inostics, Inc., Mundelein, IL). 34 The ddPCR and BEAMing methods are enhancements of traditional PCR with improved sensitivity and specificity.
14,35 These tests can determine absolute quantification of mutant EGFR levels in plasma samples and could be used to serially monitor treatment response or failure and disease progression. 36 Comparison of the cobas test with the BEAMing test for detection of the T790M mutation in plasma samples has revealed that the BEAMing test has a higher sensitivity whereas the cobas test has a higher specificity than tissue testing. 14 Detection of the T790M mutation in patients with advanced NSCLC is important to guide clinical decisions. Collectively, the results of this study support the clinical utility of the cobas plasma test for detection of the EGFR T790M mutation in patients with advanced NSCLC.
